about
Dysfunction in Patients With Small-for-Size Grafts After Living Donor Liver Transplantation.Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volumeKorean Patients Undergoing Deceased Donor Liver Transplantation for Alcoholic Liver Disease Have Non-Inferior Survival Outcomes than for Hepatitis B Virus: a Real-World Experience without Minimum Abstinence before TransplantationImpact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.Optimal tailored screening protocol after living donor liver transplantation for hepatocellular carcinomaFeasibility of implementing a surgical student internship program in South Korea.Heterogeneous living donor hepatic fat distribution on MRI chemical shift imagingClinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinomaResponse-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver TransplantationBile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinomaFatigue and related factors after liver transplantation.A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation PatientsFalse Positive Diagnosis of Hepatocellular Carcinoma in Liver Resection Patients.Long term outcomes of pediatric liver transplantation according to age.Living donor liver transplantation for an infant with osteogenesis imperfecta and intrahepatic cholestasis: report of a case.Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting.Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.Clinical and economic evaluation of pharmacists' contribution to patient care on a multi-disciplinary liver transplant team.Reappraisal of the Role of Portacaval Shunting in the Growth of Patients With Glycogen Storage Disease Type I in the Era of Liver Transplantation.Living donor liver transplantation: the Asian perspective.Hepatic Steatosis: Assessment with Acoustic Structure Quantification of US Imaging.Inexplicable Outcome of Early Appearance of Hepatocellular Carcinoma in the Allograft After Deceased Donor Liver Transplantation: A Case Report.What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma?Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.Renal outcomes after liver transplantation in fulminant hepatitis A with acute kidney injury: comparison with hepatorenal syndrome.Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease.Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In VivoOutcome and technical aspects of liver retransplantation: analysis of 25-year experience in a single major center.Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.Fulminant hepatitis linked to dapsone hypersensitivity syndrome requiring urgent living donor liver transplantation: a case report.The "ABO cross-transplantation problem" in liver transplantation in Korea.The right posterior bile duct anatomy of the donor is important in biliary complications of the recipients after living-donor liver transplantation.Outcome of various treatments for posttransplant hepatitis B virus recurrence.Usefulness of preoperative C-reactive protein and alpha-fetoprotein levels for prognostication of patients with hepatocellular carcinoma after living donor liver transplantation.Hepatic venous congestion in living donor grafts in liver transplantation: is there an effect on hepatocellular carcinoma recurrence?Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
P50
Q33421276-A6C93660-DE7C-4804-92DB-C1D5BB281DC0Q33627543-8365DEEB-B4CE-4A8F-B344-148DBF3F7FAEQ33661455-9B0DBFBA-13EC-4F0B-8543-922160A19D51Q33905617-975CF477-AA72-4CD5-A89C-B756722EC0BEQ34339626-D951D974-A995-4CB7-BDFE-155E42903084Q34429511-A5CB88FE-CD63-4B54-8A1C-A2F2A88BB873Q35257379-856C2150-3CB9-4405-A056-AB7564E410F3Q35782486-428D1D64-FFA9-4046-852D-BC55EC27EAA6Q35811132-6F6BE5CE-9AD4-4F81-8294-2272B9D99E29Q36241697-360B6E69-83B6-4BE6-B2BB-2DD0057B20F4Q36383856-9ED5E244-70E4-4AF7-968F-725CD55DF56EQ36383860-B1CADC38-B699-4A56-8AE8-15536C2FFD16Q36432130-4850DF25-A9DD-48A9-8F41-134CE5C5BD3EQ36989752-8A4C2CAA-4AE5-4160-921E-564A1264CA05Q37323392-14A41588-7AC3-4305-8BE4-7207AB9CBDBCQ37570229-D93A3A9D-E769-4752-9D65-566478799F9DQ37622179-132BD530-04A7-4496-AC8C-C1116955F1CDQ37622249-B3623738-2E96-4BC3-AC67-FBE93DBEFE1EQ38187434-29FBC0B2-B6DA-4D3B-B0AF-F356E9DC2822Q38192013-14A2291E-FEBF-4E43-88E4-850590024313Q38419184-409C8516-437E-4A27-AE38-90667E2D7D5DQ38422548-A9FEBFBE-550D-4DBB-AB71-37376FBEE54BQ38438031-180EB12E-D048-4B12-906A-84EC4250558EQ38539798-A045BA34-9AEE-44BA-AE6A-58D6A008B820Q38680290-712BF5CA-FA77-474F-8096-8122FB1011ACQ38837109-AF254A43-25A8-4B69-B54D-328645C4E658Q40220215-E820D598-0A5B-417C-8EE9-8EC69D81F4ABQ41043133-A3E4B84D-E7EA-46C2-B099-598D177724A8Q41100532-EE7F0556-C501-44A7-B9AF-ADEC4B44B19CQ41285493-1299C220-90AA-446C-AA1E-6DD047F6B9C2Q41309979-10624EB2-B01A-4F99-BF6B-54D1E8886E46Q41628518-002C9F70-F303-4E37-88F9-F10113E91DC1Q41695358-6E710ECA-8B4E-43D0-96EE-132C7D27585AQ42200345-75474288-B39D-4705-96EA-08AE8EAE02A8Q42624867-DD342B2F-D5A2-400F-ADD6-F8AFA854F0A7Q43615717-E0518945-0FE9-4BA0-8177-052A903BCF22Q43714307-ACF22655-8581-4B20-92A4-2099541FE6FAQ43842313-7C1AFA3A-79F6-44F8-B5E7-EDD348260ED6Q44606962-6241CBBB-DF97-4B73-81B7-1CD3ADD61144Q45175992-ADC92A49-DC1A-4A78-9DA8-B0EA6E34BDE9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nam-Joon Yi
@ast
Nam-Joon Yi
@en
Nam-Joon Yi
@es
Nam-Joon Yi
@sl
type
label
Nam-Joon Yi
@ast
Nam-Joon Yi
@en
Nam-Joon Yi
@es
Nam-Joon Yi
@sl
prefLabel
Nam-Joon Yi
@ast
Nam-Joon Yi
@en
Nam-Joon Yi
@es
Nam-Joon Yi
@sl
P106
P31
P496
0000-0002-5467-425X